Login / Signup

Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.

Hendrik Schulze-KoopsKlaus KruegerInka VallbrachtRebecca HasseliAlla Skapenko
Published in: Annals of the rheumatic diseases (2020)
Keyphrases
  • coronavirus disease
  • sars cov
  • diffuse large b cell lymphoma
  • early onset
  • oxidative stress
  • hodgkin lymphoma
  • chronic lymphocytic leukemia
  • respiratory syndrome coronavirus
  • drug induced